Your session is about to expire
← Back to Search
Alkylating agents
Evomela for Multiple Myeloma (AHCT Trial)
Phase < 1
Recruiting
Led By Ehsan Malek, MD
Research Sponsored by Ehsan Malek
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1, 8, 15, and 52
Awards & highlights
AHCT Trial Summary
This trial is testing whether a lower dose of melphalan, a chemotherapy drug used in stem cell transplants, is effective in treating Multiple Myeloma cells.
Eligible Conditions
- Multiple Myeloma
AHCT Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ days 1, 8, 15, and 52
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1, 8, 15, and 52
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Residual myeloma cell number measured by NGS
Secondary outcome measures
Percent of participants with diarrhea and oral mucositis and other non-hematologic toxicities
Percent of participants with engraftment failure
Percent of participants with post-transplant period safety
+3 moreAHCT Trial Design
1Treatment groups
Experimental Treatment
Group I: Evomela (Melphalan)Experimental Treatment5 Interventions
Participants will receive Evomela 16 mg/m2 on day 1 of the study only. Evomela will be given as IV infusion over 30 minutes after administration of 500 cc normal saline as pre-hydration and pre-medications Prochlorperazine, Acetaminophen, and Diphenhydramine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Diphenhydramine
2002
Completed Phase 4
~1170
Prochlorperazine
2015
Completed Phase 4
~550
Next Generation Sequencing
2018
N/A
~260
Acetaminophen
2017
Completed Phase 4
~2030
Find a Location
Who is running the clinical trial?
Ehsan MalekLead Sponsor
Ehsan Malek, MDPrincipal InvestigatorUniversity Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
5 Previous Clinical Trials
119 Total Patients Enrolled
5 Trials studying Multiple Myeloma
119 Patients Enrolled for Multiple Myeloma
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How is Next Generation Sequencing typically applied in current medical practices?
"By employing Next Generation Sequencing, neuralgia, cutaneous irritation, and whiplash syndrome can all be successfully managed."
Answered by AI
How many participants can the trial accommodate?
"Affirmative. The information on clinicaltrials.gov verifies that this research trial, which was first presented on December 1st 2022, is actively looking for participants in the study. Approximately 20 individuals need to be enrolled from a single medical site."
Answered by AI
Share this study with friends
Copy Link
Messenger